Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 26, 2023
Discovery & Translation
Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID vaccine and more
BioCentury’s roundup of translational news
BioCentury | Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Jan 31, 2023
Distillery Therapeutics
Inhibiting excess protein degradtion for fragile X syndrome
BioCentury | Nov 30, 2022
Discovery & Translation
Acuitas’ pan-influenza mRNA vaccine; plus Opna links FMR1 to cancer and more
BioCentury’s roundup of translational news
BioCentury | Apr 25, 2022
Data Byte
Mechanistic diversity in the pipeline for fragile X syndrome
The fragile X pipeline comprises as many drugs targets as drug candidates
BioCentury | Jan 1, 2021
Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Mar 25, 2019
Distillery Therapeutics
Two promoters of FMR1 expression to treat Fragile X syndrome
Items per page:
1 - 10 of 37